Dergiler / Medicine Science / 2012 / Cilt: 1 Sayı: 2

HDL-C as a new therapeutic target in the treatment of dyslipidemia

Sayfa
141–149
Yayın Tarihi
2012-06-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this regards, apo-AI analogs, acute HDL-C infusions therapies and new cholesteryl ester transfer protein CETP inhibitors have opened new expectations in the treatment of CVD.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Clinical and epidemiological studies have suggested that low plasma levels of high-density lipoproteins cholesterol (HDL-C) are independently associated with an increased risk of cardio-vascular diseases (CVD).
📊
Temel Bulgular & Veri:Accumulated data from epidemiologic, animal models and clinical studies support the view that raising HDL may be an effective new target to decrease cardio-vascular risks.
💡
Sonuç & Katkı:In this regards, apo-AI analogs, acute HDL-C infusions therapies and new cholesteryl ester transfer protein CETP inhibitors have opened new expectations in the treatment of CVD.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:HDL · cardiovascular risks · treatment

Özet

Clinical and epidemiological studies have suggested that low plasma levels of high-density lipoproteins cholesterol (HDL-C) are independently associated with an increased risk of cardio-vascular diseases (CVD). Accumulated data from epidemiologic, animal models and clinical studies support the view that raising HDL may be an effective new target to decrease cardio-vascular risks. New insights in the understanding of the physiology, mechanisms and pathways by which HDL may reduce atherosclerosis allow new promising agents for increasing plasma HDL-C. In this regards, apo-AI analogs, acute HDL-C infusions therapies and new cholesteryl ester transfer protein CETP inhibitors have opened new expectations in the treatment of CVD.

Abstract

Clinical and epidemiological studies have suggested that low plasma levels of high-density lipoproteins cholesterol (HDL-C) are independently associated with an increased risk of cardio-vascular diseases (CVD). Accumulated data from epidemiologic, animal models and clinical studies support the view that raising HDL may be an effective new target to decrease cardio-vascular risks. New insights in the understanding of the physiology, mechanisms and pathways by which HDL may reduce atherosclerosis allow new promising agents for increasing plasma HDL-C. In this regards, apo-AI analogs, acute HDL-C infusions therapies and new cholesteryl ester transfer protein CETP inhibitors have opened new expectations in the treatment of CVD.

🔖

Bu Makaleye Atıf Yap

I, S. (2012). HDL-C as a new therapeutic target in the treatment of dyslipidemia. Medicine Science, Cilt: 1 Sayı: 2, 141–149. https://ajindex.com/articles/1003371

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. ) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002
  2. ) Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007
  3. ) Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994
  4. 1383–89. ) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996
  5. 1001–09. ) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977
  6. ) The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010
  7. 1563–1574. ) Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005
  8. ) Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983
  9. ) Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH. Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995
  10. 1196 –1201. ) Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986
  11. 256(20):2835-2838. ) Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cho- lesterol levels, triglycerides, lipoprotein(a), apolipo roteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001
  12. 104(10):1108- 1113. ) Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Cast